Trial Profile
Treatment of Peripheral T-Cell Lymphoma With Aggressive Induction Chemotherapy Followed by Autologous Stem Cell Transplant Using Denileukin Diftitox (Ontak) for in-Vivo Purging and Post-Transplant Therapy: A Multicenter Phase II Clinical Trial
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Denileukin diftitox (Primary) ; Carmustine; Cyclophosphamide; Cytarabine; Doxorubicin; Doxorubicin liposomal; Etoposide; Gemcitabine; Granulocyte colony-stimulating factors; Methotrexate; Pegfilgrastim; Prednisone; Vincristine; Vinorelbine
- Indications Non-Hodgkin's lymphoma; Peripheral T-cell lymphoma
- Focus Therapeutic Use
- 14 Apr 2020 Status changed from active, no longer recruiting to discontinued.
- 13 Aug 2013 Planned end date changed from 1 Jun 2013 to 1 Dec 2014 as reported by ClinicalTrials.gov.
- 12 Apr 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.